260 related articles for article (PubMed ID: 15853918)
1. Reduced release of intact and cleaved urokinase receptor in stimulated whole-blood cultures from human immunodeficiency virus-1-infected patients.
Ostrowski SR; Piironen T; Høyer-Hansen G; Gerstoft J; Pedersen BK; Ullum H
Scand J Immunol; 2005 Apr; 61(4):347-56. PubMed ID: 15853918
[TBL] [Abstract][Full Text] [Related]
2. Plasma levels of intact and cleaved urokinase receptor decrease in HIV-1-infected patients initiating highly active antiretroviral therapy.
Ostrowski SR; Katzenstein TL; Pedersen M; Høyer-Hansen G; Gerstoft J; Pedersen BK; Ullum H
Scand J Immunol; 2006 Jun; 63(6):478-86. PubMed ID: 16764702
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-6 infusion during human endotoxaemia inhibits in vitro release of the urokinase receptor from peripheral blood mononuclear cells.
Ostrowski SR; Plomgaard P; Fischer CP; Steensberg AS; Møller K; Høyer-Hansen G; Pedersen BK; Ullum H
Scand J Immunol; 2005 Feb; 61(2):197-206. PubMed ID: 15683457
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients.
Lomholt AF; Christensen IJ; Høyer-Hansen G; Nielsen HJ
Acta Oncol; 2010 Aug; 49(6):805-11. PubMed ID: 20524776
[TBL] [Abstract][Full Text] [Related]
5. The urokinase receptor is overexpressed in the AIDS dementia complex and other neurological manifestations.
Cinque P; Nebuloni M; Santovito ML; Price RW; Gisslen M; Hagberg L; Bestetti A; Vago G; Lazzarin A; Blasi F; Sidenius N
Ann Neurol; 2004 May; 55(5):687-94. PubMed ID: 15122709
[TBL] [Abstract][Full Text] [Related]
6. Soluble urokinase receptor released from human carcinoma cells: a plasma parameter for xenograft tumour studies.
Holst-Hansen C; Hamers MJ; Johannessen BE; Brünner N; Stephens RW
Br J Cancer; 1999 Sep; 81(2):203-11. PubMed ID: 10496343
[TBL] [Abstract][Full Text] [Related]
7. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy.
Mustjoki S; Sidenius N; Sier CF; Blasi F; Elonen E; Alitalo R; Vaheri A
Cancer Res; 2000 Dec; 60(24):7126-32. PubMed ID: 11156421
[TBL] [Abstract][Full Text] [Related]
8. Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer.
Henic E; Borgfeldt C; Christensen IJ; Casslén B; Høyer-Hansen G
Clin Cancer Res; 2008 Sep; 14(18):5785-93. PubMed ID: 18794088
[TBL] [Abstract][Full Text] [Related]
9. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients.
Sier CF; Stephens R; Bizik J; Mariani A; Bassan M; Pedersen N; Frigerio L; Ferrari A; Danø K; Brünner N; Blasi F
Cancer Res; 1998 May; 58(9):1843-9. PubMed ID: 9581823
[TBL] [Abstract][Full Text] [Related]
10. Expression of the urokinase plasminogen activator and its receptor in HIV-1-associated central nervous system disease.
Sidenius N; Nebuloni M; Sala S; Zerbi P; Price RW; Gisslen M; Hagberg L; Vago L; Lazzarin A; Blasi F; Cinque P
J Neuroimmunol; 2004 Dec; 157(1-2):133-9. PubMed ID: 15579290
[TBL] [Abstract][Full Text] [Related]
11. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
[TBL] [Abstract][Full Text] [Related]
12. Excess soluble urokinase-type plasminogen activator receptor in the plasma of dialysis patients correlates with increased fibrinolytic activity.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2007; 119(4):475-80. PubMed ID: 16828495
[TBL] [Abstract][Full Text] [Related]
13. Urokinase receptor variants in tissue and body fluids.
Høyer-Hansen G; Lund IK
Adv Clin Chem; 2007; 44():65-102. PubMed ID: 17682340
[TBL] [Abstract][Full Text] [Related]
14. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
[TBL] [Abstract][Full Text] [Related]
15. Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy.
Andersen O; Eugen-Olsen J; Kofoed K; Iversen J; Haugaard SB
J Med Virol; 2008 Feb; 80(2):209-16. PubMed ID: 18098145
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B.
Zhou H; Wu X; Lu X; Chen G; Ye X; Huang J
Thromb Res; 2009; 123(3):537-42. PubMed ID: 18691743
[TBL] [Abstract][Full Text] [Related]
17. High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients.
Ostrowski SR; Piironen T; Høyer-Hansen G; Gerstoft J; Pedersen BK; Ullum H
J Acquir Immune Defic Syndr; 2005 May; 39(1):23-31. PubMed ID: 15851910
[TBL] [Abstract][Full Text] [Related]
18. Soluble urokinase plasminogen activator receptor in blood transfusion components.
Riisbro R; Brünner N; Christensen IJ; Nielsen HJ
Transfus Med; 2004 Aug; 14(4):305-12. PubMed ID: 15285727
[TBL] [Abstract][Full Text] [Related]
19. The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortality.
Wittenhagen P; Kronborg G; Weis N; Nielsen H; Obel N; Pedersen SS; Eugen-Olsen J
Clin Microbiol Infect; 2004 May; 10(5):409-15. PubMed ID: 15113317
[TBL] [Abstract][Full Text] [Related]
20. Soluble urokinase-type plasminogen activator receptor forms in plasma as markers of atherosclerotic plaque vulnerability.
Olson FJ; Thurison T; Ryndel M; Høyer-Hansen G; Fagerberg B
Clin Biochem; 2010 Jan; 43(1-2):124-30. PubMed ID: 19822140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
